Illumina (NASDAQ:ILMN) Given New $210.00 Price Target at Citigroup

Illumina (NASDAQ:ILMN – Free Report) had its price target raised by Citigroup from $113.00 to $210.00 in a report published on Monday,Benzinga reports. The firm currently has a sell rating on the life sciences company’s stock.

Several other equities research analysts have also commented on the stock. Stephens lowered shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price target on the stock. in a report on Friday, October 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Illumina in a research report on Monday, August 31st. Royal Bank Of Canada increased their price target on Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $135.00 to $260.00 in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. decreased their price objective on Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a report on Friday. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $244.24.

View Our Latest Stock Analysis on Illumina

Illumina Stock Performance

ILMN opened at $226.58 on Monday. Illumina has a 12-month low of $112.65 and a 12-month high of $309.35. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $34.21 billion, a PE ratio of 56.08, a P/E/G ratio of 4.09 and a beta of 1.41. The firm has a 50 day moving average of $249.44 and a two-hundred day moving average of $176.58.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.36 by $0.26. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 EPS. On average, analysts anticipate that Illumina will post 5.43 EPS for the current year.

Insider Buying and Selling

In related news, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. This represents a 13.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,603,377 shares of company stock worth $344,738,717 in the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Institutional Trading of Illumina

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Signature Equity Partners LLC grew its position in shares of Illumina by 246.5% in the third quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 106 shares in the last quarter. Fiduciary Financial Advisors purchased a new position in Illumina during the second quarter worth approximately $26,000. MCF Advisors LLC lifted its position in Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after buying an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. acquired a new position in Illumina during the second quarter worth $32,000. Finally, Rakuten Securities Inc. acquired a new position in Illumina during the second quarter worth $33,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

  • Positive Sentiment: Management raised full-year revenue and earnings guidance, while reporting healthy margins and solid free cash flow. Clinical sequencing demand and strong placements of the NovaSeq X platform are supporting potential margin and earnings expansion. The top 5 analyst questions from Illumina’s Q3 earnings call
  • Positive Sentiment: International revenue trends and growth opportunities in clinical applications could provide support for Wall Street forecasts, particularly as new offerings such as the BioInsight software suite gain traction. International revenue trends
  • Neutral Sentiment: Industry research projects the global forensic technologies and services market will grow from $24 billion in 2024 to $44.7 billion by 2030, potentially benefiting companies involved in advanced DNA sequencing and AI-enabled forensics, including Illumina. Forensic Technologies and Services Global Strategic Business Report
  • Neutral Sentiment: Zacks highlighted Illumina as a potential long-term growth stock, but this view has not offset near-term concerns about valuation and the earnings reaction. Why Illumina is a Top Growth Stock for the Long-Term
  • Negative Sentiment: The third-quarter report triggered a sharp selloff even though earnings exceeded expectations and guidance improved. Investors appeared more concerned about the stock’s rich valuation—roughly 40 times trailing earnings—and the gap between strong clinical demand and weaker research and applied markets. Illumina Stock Falls After Q3 Results Lift Guidance
  • Negative Sentiment: Citigroup raised its price target from $113 to $210 but maintained a Sell rating, implying further downside from the referenced trading level. The higher target reflects a more favorable valuation assessment, but the rating remains a direct negative signal. Citigroup analyst recommendation
  • Negative Sentiment: JPMorgan reportedly lowered its expectations for Illumina, adding to analyst pressure after the earnings release. JPMorgan lowers expectations for Illumina
  • Negative Sentiment: The stock moved below its 50-day moving average following an analyst downgrade, reinforcing short-term technical weakness and potentially encouraging additional selling. Illumina crosses below 50-day moving average

Illumina Company Profile

(Get Free Report)

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

Recommended Stories

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.